Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
306.4 INR | +5.06% | +17.10% | +22.73% |
Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.73% | 4.18B | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.73% | 22.02B | |
-17.84% | 20.9B | |
-9.28% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon : Signs Settlement Agreement with US-Based Celgene in Cancer-Treatment Drug Patent Case